147 related articles for article (PubMed ID: 38884591)
1. Diagnostic guide for immune checkpoint inhibitor-induced liver injury.
Ito T; Takeuchi Y; Mizuno K; Imai M; Yoshimaru Y; Abe K; Abe M; Matsuura T; Yokode M; Shiokawa M; Kodama Y; Komuta M; Harada K; Tanaka A
Hepatol Res; 2024 Jun; ():. PubMed ID: 38884591
[TBL] [Abstract][Full Text] [Related]
2. Computed tomography findings of hepatobiliary systems in patients with immune checkpoint inhibitor-induced liver injury.
Masuoka S; Hiyama T; Kuno H; Sasaki T; Oda S; Miyasaka Y; Yamaguchi M; Kobayashi T
Abdom Radiol (NY); 2023 Sep; 48(9):3012-3021. PubMed ID: 37294454
[TBL] [Abstract][Full Text] [Related]
3. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort.
Hountondji L; Ferreira De Matos C; Lebossé F; Quantin X; Lesage C; Palassin P; Rivet V; Faure S; Pageaux GP; Assenat É; Alric L; Zahhaf A; Larrey D; Witkowski Durand Viel P; Riviere B; Janick S; Dalle S; Maria ATJ; Comont T; Meunier L
JHEP Rep; 2023 Jun; 5(6):100719. PubMed ID: 37138674
[TBL] [Abstract][Full Text] [Related]
4. Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management.
Pi B; Wang J; Tong Y; Yang Q; Lv F; Yu Y
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e858-e867. PubMed ID: 34482313
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047
[TBL] [Abstract][Full Text] [Related]
6. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents.
Suzman DL; Pelosof L; Rosenberg A; Avigan MI
Liver Int; 2018 Jun; 38(6):976-987. PubMed ID: 29603856
[TBL] [Abstract][Full Text] [Related]
7. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy.
Hirasawa Y; Yoshimura K; Matsui H; Kubota Y; Ishida H; Arai J; Sakaki M; Oguro N; Shida M; Taniguchi M; Hamada K; Ariizumi H; Ishiguro T; Ohkuma R; Sambe T; Horiike A; Imamura CK; Shiozawa E; Wada S; Tsurutani J; Iwamoto S; Uchida N; Kiuchi Y; Tate G; Kobayashi S; Tsunoda T
Medicine (Baltimore); 2021 Jun; 100(23):e25774. PubMed ID: 34114983
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy.
Zen Y; Yeh MM
Semin Diagn Pathol; 2019 Nov; 36(6):434-440. PubMed ID: 31358424
[TBL] [Abstract][Full Text] [Related]
9. Cholangitis Induced by Immune Checkpoint Inhibitors: Analysis of Pharmacovigilance Data.
Meunier L; Hountondji L; Jantzem H; Faillie JL; Maria A; Palassin P;
Clin Gastroenterol Hepatol; 2024 Jul; 22(7):1542-1545.e4. PubMed ID: 38110061
[TBL] [Abstract][Full Text] [Related]
10. Hepatobiliary and Pancreatic Adverse Events.
Zhang HC; Wang LS; Miller E
Adv Exp Med Biol; 2021; 1342():339-355. PubMed ID: 34972973
[TBL] [Abstract][Full Text] [Related]
11. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies.
Mizuno K; Ito T; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Kawashima H; Inukai Y; Toyoda H; Yokota K; Hase T; Maeda O; Kiyoi H; Nagino M; Hibi H; Kodera Y; Fujimoto Y; Sone M; Gotoh M; Ando Y; Akiyama M; Hasegawa Y; Fujishiro M
J Gastroenterol; 2020 Jun; 55(6):653-661. PubMed ID: 32124082
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy.
Kawano M; Yano Y; Yamamoto A; Yasutomi E; Inoue Y; Kitadai J; Yoshida R; Matsuura T; Shiomi Y; Ueda Y; Kodama Y
Diagnostics (Basel); 2024 Apr; 14(8):. PubMed ID: 38667461
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of immune checkpoint inhibitor-induced liver toxicity managed by hepatologists in a multidisciplinary toxicity team.
Ito T; Mizuno K; Yamamoto T; Yasuda T; Yokoyama S; Yamamoto K; Imai N; Ishizu Y; Honda T; Hama M; Kataoka T; Shimokata T; Ando Y; Kawashima H
Hepatol Res; 2024 Apr; ():. PubMed ID: 38571477
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment.
Okuno T; Nakashima K; Mitarai Y; Kataoka M; Tobita H; Nagase M; Isobe T; Tsubata Y
Respir Med Case Rep; 2022; 40():101773. PubMed ID: 36408484
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment.
Okuno T; Nakashima K; Mitarai Y; Kataoka M; Tobita H; Nagase M; Isobe T; Tsubata Y
Respir Med Case Rep; 2022; 40():101753. PubMed ID: 36217354
[TBL] [Abstract][Full Text] [Related]
16. Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies.
Ito T; Ishigami M; Yamamoto T; Mizuno K; Yamamoto K; Imai N; Ishizu Y; Honda T; Kawashima H; Yasuda S; Toyoda H; Yokota K; Hase T; Nishio N; Maeda O; Kato M; Hashimoto N; Hibi H; Kodera Y; Sone M; Ando Y; Akiyama M; Shimoyama Y; Fujishiro M
Hepatol Int; 2021 Oct; 15(5):1278-1287. PubMed ID: 34373964
[TBL] [Abstract][Full Text] [Related]
17. A novel pathologic marker, indoleamine 2,3-dioxygenase 1, for the cholangiopathy of immune checkpoint inhibitors-induced immune mediated hepatotoxicity as adverse events and the prediction of additional ursodeoxycholic acid treatment.
Yoshimura K; Tamano Y; Nguyen Canh H; Zihan L; Le Thanh D; Sato Y; Terashima T; Shimoda S; Harada K
Med Mol Morphol; 2023 Jun; 56(2):106-115. PubMed ID: 36599971
[TBL] [Abstract][Full Text] [Related]
18. Hepatobiliary Adverse Events.
Abu-Sbeih H; Wang Y
Adv Exp Med Biol; 2020; 1244():271-276. PubMed ID: 32301021
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor-related hepatotoxicity: A review.
Remash D; Prince DS; McKenzie C; Strasser SI; Kao S; Liu K
World J Gastroenterol; 2021 Aug; 27(32):5376-5391. PubMed ID: 34539139
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Pathological Features of Immune Checkpoint Inhibitor-induced Liver Injury in Comparison with Drug-induced Liver Injury and Autoimmune Hepatitis.
Sunago K; Abe M; Yoshida O; Watanabe T; Nakamura Y; Imai Y; Koizumi Y; Hirooka M; Tokumoto Y; Hiasa Y
J Gastrointestin Liver Dis; 2023 Dec; 32(4):488-496. PubMed ID: 38147620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
